Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Dana-Farber Cancer Institute
P

EHA/ASH 2020 Update on mAbs for R/R Multiple Myeloma: Is the Addition of Isatuximab or Daratumumab to Kd Beneficial vs. Kd Alone?

By Dana-Farber Cancer Institute FEATURING Paul Richardson
By Dana-Farber Cancer Institute FEATURING Paul Richardson
156 views
January 19, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Myeloma
19:24
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Updates on Managing Newly Diagnosed MM - In…

Feat. P. Richardson
15:13
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Mezigdomide + Dex + Dara or Elo in Pts With…

Feat. P. Richardson
15:49
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 DEBATE: Early HDM-aSCT in MM Is No Longer the SoC

Feat. C. Mo
16:25
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Treatment of the Frail MM Patients - Personalized Care

Feat. B. O'Donnell
09:52
Insights from 2023 IMS Annual Meeting

IMS 2023 Insights: "Epigenetic Regulation of CD38/48 by KDM6A a…

Feat. J. Liu
11:35
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Updated Phase I Study Results of PHE885, …

Feat. A. Sperling
32:03
Indy Hematology Review

Emerging and Current Treatment of MM: What Should We Know and What S…

Feat. K. Anderson
41:46
Yale Cancer Center

Early Detection and Interception in Myeloma: The PROMISE Study

Feat. I. Ghobrial
36:59
Dana-Farber Cancer Institute

Updates on Managing Bone Disease in Multiple Myeloma

Feat. M. Hartley-Brown
23:11
Dana-Farber Cancer Institute

Bispecific Antibodies in Multiple Myeloma

Feat. O. Nadeem
54:12
Dana-Farber Cancer Institute

Symptom Management in Multiple Myeloma

Feat. S. Midha
23:40
Dana-Farber Cancer Institute

Update on CAR T-Cells in Multiple Myeloma

Feat. A. Sperling
34:40
Dana-Farber Cancer Institute

Updates on AL Amyloidosis Treatment: What is New in 2023

Feat. G. Bianchi
48:46
Dana-Farber Cancer Institute

The Ongoing Evolution of Systemic Therapy for ND Multiple Myeloma

Feat. C. Mo
47:04
Dana-Farber Cancer Institute

Future Directions for Novel & Next Gen Therapy in the Management…

Feat. P. Richardson
20:28
Dana-Farber Cancer Institute

The PROMISE of Early Detection and Interception in Myeloma

Feat. I. Ghobrial
44:49
Dana-Farber Cancer Institute

Recent Updates in Multiple Myeloma

Feat. K. Anderson
26:24
Dana-Farber Cancer Institute

Myeloma 101: Diagnosis, Prognosis & Risk

Feat. N. Munshi
10:37
ASH 2022 Conference Coverage

ASH 2022 Mezigdomide (CC-92480) + Dex in R/R MM: Preliminary Results…

Feat. P. Richardson
10:37
ASH 2022 Conference Coverage

ASH 2022 Subsequent Antimyeloma Therapies From ICARIA-MM Study: Pom/…

Feat. P. Richardson
24:19
Dana-Farber Cancer Institute

Phase 3 DETERMINATION Trial: RVd ± ASCT & Lenalidomide Maintenan…

Feat. P. Richardson
12:09
Dana-Farber Cancer Institute

2022 Treatment Landscape and Future Directions of R/R Multiple Myelo…

Feat. N. Munshi
08:51
Dana-Farber Cancer Institute

EHA 2020 ICARIA-MM Data on Isatuximab in R/R Multiple Myeloma: Does …

Feat. P. Richardson
06:23
Dana-Farber Cancer Institute

EHA/ASH 2020 Update on mAbs for R/R Multiple Myeloma: Is the Additio…

Feat. P. Richardson
19:38
Dana-Farber Cancer Institute

Waldenström Macroglobulinemia - Standard Treatment Options and Revie…

Feat. J. Castillo
12:07
Dana-Farber Cancer Institute

Waldenström Macroglobulinemia: Diagnostic criteria, Why Not Treat Ev…

Feat. J. Castillo
17:47
Dana-Farber Cancer Institute

Relapse Refractory Myeloma and Novel Treatments

Feat. N. S. Raje
16:28
Dana-Farber Cancer Institute

Is it Time to Treat Patients with Smoldering Myeloma in 2018?

Feat. I. Ghobrial
35:43
Dana-Farber Cancer Institute

2016 Multiple Myeloma Patient Education Symposium: Novel Treatments …

Feat. N. S. Raje